NCT02476409View on ClinicalTrials.gov

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 13, 2021

Study Completion Date

May 13, 2021

Conditions
Congestive Heart Failure
Interventions
DRUG

tolvaptan

Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.

OTHER

Placebo

Placebo for tolvaptan

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT02476409 - Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders | Biotech Hunter | Biotech Hunter